Nothing Special   »   [go: up one dir, main page]

CL2014003135A1 - Formulacion que comprende un quelato de oligonucleotidos; y sus usos. - Google Patents

Formulacion que comprende un quelato de oligonucleotidos; y sus usos.

Info

Publication number
CL2014003135A1
CL2014003135A1 CL2014003135A CL2014003135A CL2014003135A1 CL 2014003135 A1 CL2014003135 A1 CL 2014003135A1 CL 2014003135 A CL2014003135 A CL 2014003135A CL 2014003135 A CL2014003135 A CL 2014003135A CL 2014003135 A1 CL2014003135 A1 CL 2014003135A1
Authority
CL
Chile
Prior art keywords
formulation
oligonucleotide chelate
chelate
oligonucleotide
Prior art date
Application number
CL2014003135A
Other languages
English (en)
Inventor
Michel Bazinet
Andrew Vaillant
Original Assignee
Replicor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Replicor Inc filed Critical Replicor Inc
Publication of CL2014003135A1 publication Critical patent/CL2014003135A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7115Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/712Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7125Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135Compounds containing heavy metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • A61P31/22Antivirals for DNA viruses for herpes viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
CL2014003135A 2012-05-18 2014-11-18 Formulacion que comprende un quelato de oligonucleotidos; y sus usos. CL2014003135A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261648694P 2012-05-18 2012-05-18

Publications (1)

Publication Number Publication Date
CL2014003135A1 true CL2014003135A1 (es) 2015-01-09

Family

ID=49581827

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003135A CL2014003135A1 (es) 2012-05-18 2014-11-18 Formulacion que comprende un quelato de oligonucleotidos; y sus usos.

Country Status (37)

Country Link
US (1) US9616083B2 (es)
EP (1) EP2849760B1 (es)
JP (2) JP6294308B2 (es)
KR (1) KR101975915B1 (es)
CN (1) CN104379152B (es)
AR (1) AR091065A1 (es)
AU (1) AU2013262415B2 (es)
BR (1) BR112014028568B1 (es)
CA (1) CA2873526C (es)
CL (1) CL2014003135A1 (es)
CO (1) CO7131388A2 (es)
CR (1) CR20140522A (es)
CU (1) CU20140132A7 (es)
CY (1) CY1122856T1 (es)
DK (1) DK2849760T3 (es)
DO (1) DOP2014000263A (es)
EA (1) EA034799B1 (es)
EC (1) ECSP14027542A (es)
ES (1) ES2767333T3 (es)
HK (1) HK1206259A1 (es)
HR (1) HRP20200045T1 (es)
HU (1) HUE047456T2 (es)
IL (1) IL235402B (es)
IN (1) IN2014DN08982A (es)
LT (1) LT2849760T (es)
MX (1) MX360626B (es)
MY (1) MY168209A (es)
NZ (1) NZ701931A (es)
PH (1) PH12014502484B1 (es)
PL (1) PL2849760T3 (es)
PT (1) PT2849760T (es)
RS (1) RS59914B1 (es)
SG (1) SG11201407261XA (es)
SI (1) SI2849760T1 (es)
TW (1) TWI648288B (es)
WO (1) WO2013170385A1 (es)
ZA (1) ZA201408082B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009054725A2 (en) 2007-10-26 2009-04-30 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
EP4043039A1 (en) 2012-01-27 2022-08-17 BioMarin Technologies B.V. Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
NZ705730A (en) 2012-08-30 2016-06-24 Replicor Inc Methods for the treatment of hepatitis b and hepatitis d infections
ME03811B (me) 2015-04-23 2021-04-20 Geron Corp Postupci za pripremu polinukleotida upotrebom kompozicija multivalentne katjonske soli
CN108513546A (zh) 2015-10-28 2018-09-07 克里斯珀医疗股份公司 用于治疗杜氏肌营养不良症的材料和方法
WO2017106926A1 (en) 2015-12-23 2017-06-29 Queensland University Of Technology Nucleic acid oligomers and uses therefor
US11166976B2 (en) 2018-11-08 2021-11-09 Aligos Therapeutics, Inc. S-antigen transport inhibiting oligonucleotide polymers and methods
WO2022229350A2 (en) 2021-04-30 2022-11-03 Tirmed Pharma Ab Single-stranded oligonucleotides for use in the medical treatment and/or prophylaxis of virus infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2158834C (en) * 1993-04-01 2004-12-07 Brenda F. Baker Antisense oligos which interfere with mrna cap activity and inhibit translation
US20020166764A1 (en) * 1997-08-12 2002-11-14 University Of Southern California Electrochemical sensor devices and methods for fast, reliable, and sensitive detection and quantitation of analytes
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
CN1694959A (zh) * 2002-09-13 2005-11-09 雷普利瑟公司 非序列互补的抗病毒寡核苷酸
KR101360955B1 (ko) * 2002-09-13 2014-02-10 레플리코르 인코포레이티드 비서열 상보적 항바이러스 올리고뉴클레오티드
EP1802643A1 (en) * 2004-10-19 2007-07-04 Replicor Inc. Antiviral oligonucleotides
US20090215873A1 (en) 2005-09-29 2009-08-27 Andrew Vaillant Therapeutic Molecules and their Uses
US8101585B2 (en) * 2006-08-04 2012-01-24 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of JNK proteins
WO2009065181A1 (en) * 2007-11-21 2009-05-28 Apollo Life Sciences Limited Nanostructures suitable for delivery of agents
AU2009221064B2 (en) * 2008-03-07 2014-12-11 Roche Innovation Center Copenhagen A/S Pharmaceutical compositions for treatment of microRNA related diseases
EP2408796B1 (en) * 2009-03-16 2020-04-22 Ionis Pharmaceuticals, Inc. Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III
JP5960049B2 (ja) * 2009-05-28 2016-08-02 クルナ・インコーポレーテッド 抗ウイルス遺伝子に対する天然アンチセンス転写物の抑制による抗ウイルス遺伝子関連疾患の治療
SI2605794T1 (sl) * 2010-08-20 2017-01-31 Replicor Inc. Oligonukleotidni kelatni kompleksi

Also Published As

Publication number Publication date
ZA201408082B (en) 2015-12-23
TW201408689A (zh) 2014-03-01
DK2849760T3 (da) 2020-02-03
JP2018058853A (ja) 2018-04-12
ECSP14027542A (es) 2015-12-31
JP6294308B2 (ja) 2018-03-14
IL235402B (en) 2022-01-01
PH12014502484A1 (en) 2015-01-12
CU20140132A7 (es) 2015-02-26
HRP20200045T1 (hr) 2020-03-20
LT2849760T (lt) 2020-04-10
HK1206259A1 (en) 2016-01-08
AR091065A1 (es) 2014-12-30
MY168209A (en) 2018-10-15
CN104379152B (zh) 2018-10-30
WO2013170385A1 (en) 2013-11-21
KR101975915B1 (ko) 2019-05-08
CO7131388A2 (es) 2014-12-01
TWI648288B (zh) 2019-01-21
BR112014028568B1 (pt) 2022-02-15
EA201401276A1 (ru) 2015-04-30
PT2849760T (pt) 2020-01-24
NZ701931A (en) 2016-06-24
SG11201407261XA (en) 2014-12-30
CR20140522A (es) 2014-12-10
US9616083B2 (en) 2017-04-11
HUE047456T2 (hu) 2020-04-28
PH12014502484B1 (en) 2015-01-12
IL235402A0 (en) 2014-12-31
PL2849760T3 (pl) 2020-05-18
EA034799B1 (ru) 2020-03-23
JP2015517503A (ja) 2015-06-22
ES2767333T3 (es) 2020-06-17
EP2849760A1 (en) 2015-03-25
AU2013262415B2 (en) 2017-06-22
KR20150016330A (ko) 2015-02-11
BR112014028568A2 (pt) 2020-06-02
US20130310445A1 (en) 2013-11-21
CA2873526A1 (en) 2013-11-21
AU2013262415A1 (en) 2014-11-27
SI2849760T1 (sl) 2020-03-31
DOP2014000263A (es) 2015-01-31
MX360626B (es) 2018-11-12
CA2873526C (en) 2020-08-18
CY1122856T1 (el) 2021-05-05
EP2849760B1 (en) 2019-10-30
RS59914B1 (sr) 2020-03-31
EP2849760A4 (en) 2015-03-25
IN2014DN08982A (es) 2015-05-22
CN104379152A (zh) 2015-02-25
MX2014013885A (es) 2015-05-08

Similar Documents

Publication Publication Date Title
IL269693A (en) Oligonucleotide probes and their uses
CL2014003294A1 (es) Derivados de bencimidazol-prolina; y sus usos contra disfunciones orexinergicas.
CL2014003135A1 (es) Formulacion que comprende un quelato de oligonucleotidos; y sus usos.
BR112014028602A2 (pt) formulação líquida.
CL2014003136A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos; composicion farmaceutica que los contiene y usos.
CL2015001486A1 (es) Composición que comprende agentes de control biológico.
CL2014001930A1 (es) Formulacion farmacéutica que comprende un anticuerpo angiopoyetina 2 (anti-ang2).
BR112014032222A2 (pt) dispositivo de exibição.
CL2014002954A1 (es) Composicion farmaceutica que contiene anticuerpos anti-il-23p19 y sus usos.
CO7061078A2 (es) Compuestos de enediino, conjugados de los mismos y sus usos y metodos
BR112014033077A2 (pt) combinação de vacina.
BR112014028359A2 (pt) absorvente com múltiplas zonas gráficas
BR302012004030S1 (pt) Configuração aplicada em jaqueta.
BR112015013892A2 (pt) simulador.
CL2014002616A1 (es) Anticuerpos anti-baff-anti-il-17 biespecíficos; composiciones que lo contienen y sus usos.
CL2014003104A1 (es) Colorante de polietilenimina alcoxilada y arilada; y sus usos.
CL2014003315A1 (es) Formulaciones que contienen aceite parafínico y un agente anti-sedimentación
CL2014003283A1 (es) Formulación farmacéutica.
BR112015007217A2 (pt) compostos e usos do composto
CL2014003495A1 (es) Agentes herbicidas que contienen flufenacet.
CO7061084A2 (es) Formas sólidas que comprenden inhibidores de ns5a de hcv, sus composiciones y sus usos
FR2986872B1 (fr) .
BR112015001416A2 (pt) plugue.
CL2015002389A1 (es) Composiciones herbicidas que contienen isoxabena y flufenaceto.
CL2014002083A1 (es) Tionocarbamatos y procesos de preparacion.